Breast cancer continues to be a major global health concern, specifically the HER2-positive (HER2+) subtype. While targeted therapies have improved outcomes, S100-A11 anti-HER2 resistance remains a significant barrier to achieving a pathological complete response in many patients. A recent study has highlighted how the tumor microenvironment, specifically cancer-associated fibroblasts (CAFs), actively contributes to this therapy failure through paracrine signaling.

Researchers focused on the protein S100-A11, which CAFs secrete in response to anti-HER2 treatments like trastuzumab, pertuzumab, and docetaxel (TPD). The presence of extracellular S100-A11 significantly reduces the sensitivity of tumor cells to these drugs. This process suggests that the stroma is not just a passive background but an active participant in therapeutic resistance.

The Role of the RAGE/STAT3 Axis in S100-A11 anti-HER2 resistance

The mechanism behind this resistance involves the activation of the RAGE/STAT3 signaling pathway. When CAFs release S100-A11, it binds to the Receptor for Advanced Glycation End-products (RAGE) on tumor cells. This interaction leads to increased STAT3 phosphorylation, which promotes cell survival and proliferation. Consequently, the tumor cells can bypass the inhibitory effects of HER2-targeted agents.

Fortunately, pharmacological intervention appears possible. In laboratory and xenograft models, researchers used azeliragon, a RAGE antagonist, to block this interaction. This treatment successfully attenuated the effects of S100-A11 and restored sensitivity to TPD therapy. In addition, the study found that high levels of stromal S100-A11 in patient biopsies were linked to residual disease after surgery, making it a potential biomarker for treatment response.

These findings provide a clear rationale for targeting the stroma in HER2+ breast cancer. By inhibiting the S100-A11/RAGE/STAT3 axis, clinicians may be able to overcome adaptive resistance. However, further clinical validation is necessary to confirm these results in diverse patient populations. Future strategies might combine anti-HER2 drugs with RAGE inhibitors to improve long-term survival rates.

Frequently Asked Questions

How does S100-A11 contribute to drug resistance?

S100-A11 is secreted by cancer-associated fibroblasts and activates the RAGE/STAT3 signaling axis in breast cancer cells. This activation promotes tumor cell proliferation and survival, making standard anti-HER2 therapies less effective.

What is azeliragon, and how does it help?

Azeliragon is a pharmacological antagonist of the RAGE receptor. It prevents the binding of S100-A11 to RAGE, thereby blocking the downstream signaling that causes therapy resistance in HER2-positive breast cancer.

Can S100-A11 be used as a clinical biomarker?

Yes, the study suggests that high stromal expression of S100-A11 is associated with residual disease after neoadjuvant therapy. Therefore, it may help identify patients who are likely to experience resistance to standard treatments.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.

References

Luque M et al. Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancer. Neoplasia. 2026 May 19. doi: undefined. PMID: 42155177.

Hudson B et al. RAGE inhibitor TTP488 (Azeliragon) suppresses metastasis in triple-negative breast cancer. npj Breast Cancer. 2023 Jul 13;9(1):59. doi: 10.1038/s41523-023-00564-9.

Ghanta P et al. Targeting S100A7/RAGE-driven Stat3/Serpin-E1 signaling for immunotherapy in metastatic breast cancer. ResearchGate. 2026 Apr 25. Abstract 7463.